ACS eliminates 1,000 positions due to fundraising drop

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The American Cancer Society is reducing its overall budget by approximately 30%, with cuts to non-personnel and personnel expenses as a result of a decrease in fundraising revenue.

ACS eliminated 1,000 positions across the U.S.

“We are also making a fundamental shift in how we engage and serve communities. Within a very short period of time, we had to reconfigure our entire portfolio to honor donor dollars and continue to advance our mission amid these very difficult times,” ACS officials said in a statement. “We will continue to engage with people where they live their lives, with a greater emphasis on the digital world in which we live.”

Table of Contents

YOU MAY BE INTERESTED IN

In April 2025, announcements from the two most influential biomedical agencies in the US, the FDA and the NIH, declared that both will seek to reduce and minimize animal-based testing and experimentation. These declarations sparked joy in some circles, and deep concern in others that was reflected in a 28% fall in the share price of Charles River Labs (NYSE: NYSE:CRL). 
Over the past three decades, cancer genetics has transformed precision oncology. Germline testing has advanced from single-gene Sanger sequencing to parallel sequencing of hundreds of genes, while tumor (somatic) testing has expanded with the rise of targeted therapies based on point mutations, copy number changes and other alterations. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login